Q&A: Nathan Tinker, New York Biotechnology Association

June 2, 2014
Guest Blogger

Pharmaceutical Executive

While at the 2014 New York BIO Conference (NYBIO), Applied Clinical Trials‘ Moe Alsumidaie spoke to Nathan Tinker, Executive Director at the New York Biotechnology Association.

Nathan Tinker

While at the 2014 New York BIO Conference (NYBIO), Applied Clinical Trials‘ Moe Alsumidaie spoke to Nathan Tinker, Executive Director at the New York Biotechnology Association, about challenges in early phase development.

The New York Biotechnology Association is dedicated to the development and growth of New York State-based bioscience related industries and institutions.

Moe Alsumidaie: How is NYBIO Changing?Nathan Tinker: When the organization was founded over 25 years ago, it was a biotechnology peer planning organization. However, it was clear that biopharmaceutical companies rapidly became a part of the equation. In the last two years, we have seen growth in the agricultural sciences industry, medical devices, combination therapies. Additionally, hospitals, clinicians, and payers/providers became more engaged in early-stage R&D development. Our objective is to take advantage of this culture and fully encompass what BIO has become on both national and policy fronts.

For the rest of the interview, click here.